Flubrotizolam FANAX Bars thienotriazolodiazepine research material from Raw Lab Chems
Flubrotizolam 0.5 MG Fanax Bars Price range: € 16,00 through € 472,39
Back to products
## Product Overview **Gidazepam Pellets** are described in the supplied information as a laboratory research preparation associated with gidazepam, a synthetic compound belonging to the 1,4-benzodiazepine family. The compound is distinguished by a brominated aromatic structure and a hydrazide-containing substituent. These structural characteristics provide a basis for analytical investigations involving chemical identification, chromatographic differentiation, and spectroscopic characterization. Raw Lab Chems presents this material exclusively within a Research Use Only framework. The supplied source describes compressed pellets intended for controlled laboratory examination. However, the stated presentation does not independently establish the actual chemical identity, purity, finished-unit composition, or content uniformity. The source also refers to independent analytical verification, batch consistency, and controlled manufacturing conditions. These descriptions remain supplier-provided claims until supported by documentation associated with the actual product and batch. No clinical, therapeutic, diagnostic, dietary, or consumer-oriented application is represented by this description. ## Chemical Identity & Classification Gidazepam is a synthetic compound belonging to the **1,4-benzodiazepine** chemical family. The supplied source describes it as a brominated benzodiazepine derivative containing a hydrazide functional group. Its molecular framework provides a basis for comparing gidazepam with other halogenated benzodiazepine-related compounds. The supplied source provides the following chemical-reference information: - **Common name:** Gidazepam - **Chemical classification:** Hydrazide-containing 1,4-benzodiazepine derivative - **Reported molecular formula:** C17H15BrN4O2 - **Related compound:** Desalkylgidazepam - **Reported metabolite description:** 7-Bromo-5-phenyl-1,2-dihydro-3H-1,4-benzodiazepine-2-one No CAS Registry Number or molecular weight was supplied. The reported molecular formula is reproduced from the source and does not independently establish the composition of the actual product. The source does not provide a verified salt-form designation or complete formulation specification. This distinction matters because the composition of a finished pellet may differ from the molecular formula of the named chemical. The source describes gidazepam as a compound associated with metabolic conversion to desalkylgidazepam. That relationship provides scientific context but does not establish the chemical identity or impurity profile of the actual product. Researchers seeking public chemical-reference information may consult [PubChem](https://pubchem.ncbi.nlm.nih.gov/) and confirm that any selected database entry corresponds to the intended compound and chemical form. ## Chemical & Physical Characteristics The supplied product is described as compressed pellets containing gidazepam. No product-specific inspection report, pellet-dimension specification, excipient list, or formulation-characterization record was provided. The stated physical presentation therefore remains a source-provided description. The gidazepam molecular framework contains a 1,4-benzodiazepine ring system and substituents that distinguish it from other benzodiazepine derivatives. These structural features provide a basis for analytical differentiation through chromatographic and spectroscopic techniques. However, structural similarity does not establish identical physical properties, stability, impurity profiles, or analytical behavior. The source identifies the hydrazide-containing structure as relevant to chemical and metabolic research. No product-specific hydrolysis-rate measurements, degradation data, or experimentally verified physicochemical profile accompanied this description. The source also does not provide a verified melting point, quantitative solubility profile, density, particle-size distribution, or hygroscopicity measurement. The finished pellet preparation may contain additional formulation ingredients that were not identified in the source. No verified binder, filler, coating, or excipient information accompanied the supplied material. The source recommends cool, dry storage protected from moisture. No validated stability study, degradation profile, or experimentally established shelf-life specification accompanied this recommendation. ## Purity & Analytical Verification The supplied description claims **purity of at least 98%**, with HPLC cited as a method of verification. It also refers to NMR and mass spectrometry for structural identification and batch consistency. However, no actual batch-specific Certificate of Analysis, chromatogram, NMR spectrum, mass spectrum, or independent laboratory report was provided. Accordingly, the stated purity threshold is not independently confirmed for the material described here. The source identifies LC-MS and GC-MS as analytical techniques associated with gidazepam investigation. Such methods may provide information concerning chemical identity, structural characteristics, impurity profiles, and analytical specificity. However, naming an analytical technique does not establish that it was performed on the actual product. An important distinction exists between the purity of the chemical ingredient and the composition of the finished pellet. Even if ingredient purity were independently established, that finding would not by itself verify the labeled component amount, total formulation, or consistency between individual units. The source also refers to gidazepam-related metabolic research involving desalkylgidazepam. These references provide analytical context rather than evidence of the product's verified performance in a particular laboratory method. No certified reference-material status, validated finished-unit content, or independently established purity specification is asserted. ## Quality Control & Batch Integrity The supplied source claims that individual batches undergo HPLC testing to confirm purity and labeled component content. It also describes NMR and mass-spectrometric verification, batch consistency, and Certificates of Analysis for institutional documentation. No actual certificate, independent testing record, manufacturing audit, laboratory accreditation document, or batch-specific quality-control report accompanied these statements. They therefore remain unverified supplier claims. For reproducible laboratory investigation, useful records may include supplier identification, batch number, chemical identifier, receipt date, storage history, and available analytical findings. For pellet preparations, the identity and purity of the named ingredient should be distinguished from the composition and consistency of the finished units. The supplied information does not establish independently verified content uniformity, excipient composition, or quantitative accuracy of the labeled amount. Where a material is described as suitable for reference-standard work, researchers should distinguish ordinary catalog material from a certified reference material. The supplied information does not establish certified reference-material status, metrological traceability, or an assigned measurement uncertainty. Claims of consistent purity, identity, formulation quality, or manufacturing compliance should be supported by actual analytical records rather than inferred from catalog terminology. ## Safety, Handling & Laboratory Precautions Gidazepam is a benzodiazepine-related compound requiring appropriate institutional risk assessment and controlled laboratory handling. Research personnel should consult applicable chemical-safety documentation and institutional procedures before receiving or examining the material. Laboratory precautions should address access restrictions, protective equipment, contamination prevention, accidental exposure, environmental release, and chemical-waste disposal. The compound's structural relationship to other benzodiazepines does not establish safety for human or veterinary exposure. The material should remain secured against unauthorized access and separated from food, beverages, and non-research environments. Because the actual purity and pellet composition have not been independently confirmed, laboratory documentation should distinguish verified characteristics from supplier-provided statements. The pellet presentation must not be interpreted as evidence of pharmaceutical suitability or authorization for personal use. Any accidental exposure or contamination incident should be managed according to institutional emergency procedures. ## Packaging, Labeling & Storage The supplied source describes high-barrier, moisture-resistant packaging intended to protect material integrity during transportation. No packaging-validation study, verified container specification, or actual shipment-condition record accompanied this claim. The source recommends cool, dry storage protected from moisture, with a suggested temperature range of 15–25°C. No validated stability data was provided to establish that this temperature range is necessary or sufficient for a particular shelf life. The source also claims that shipping arrangements support regulatory compliance and safe transit. No shipment classification, carrier documentation, or compliance record was supplied to substantiate those statements. Laboratory inventory records should preserve the compound name, any available batch identifier, receipt details, and relevant storage observations. The labeled pellet content should be recorded as a source-provided specification unless independently confirmed. Where chemical form or formulation ingredients remain uncertain, the inventory record should preserve those uncertainties rather than assign unverified details. Packaging and environmental requirements should be assessed using available safety documentation, relevant stability evidence, and institutional laboratory procedures. ## Intended Research Use & Market Positioning The supplied scientific context places gidazepam within analytical research involving 1,4-benzodiazepine derivatives, chemical identification, structural comparison, and forensic toxicology. Its hydrazide-containing molecular framework provides a basis for examining distinctions among related benzodiazepine compounds. The source references chromatographic identification, mass-spectrometric characterization, and investigation of gidazepam-related analytical markers. These references describe laboratory research contexts and do not establish any human-use application. The supplied Raw Lab Chems catalog references include [Gidazepam Pellets](https://rawlabchems.com/product/gidazepam-pellets-3mg/) and a [second Gidazepam Pellets listing](https://rawlabchems.com/product/gidazepam-pellets-3mg-2/). Both links identify similarly named products, but the supplied information does not establish whether they represent separate formulations, duplicate catalog entries, or different inventory records. For related benzodiazepine catalog context, Raw Lab Chems also lists [Bromonordiazepam Pellets](https://rawlabchems.com/product/buy-bromonordiazepam-pellets/). These references identify related research materials but do not establish equivalent chemical identity, purity, formulation, regulatory status, or analytical characteristics. They provide catalog context rather than evidence of certified reference-material status or interchangeability. ## Ordering, Availability & Fulfillment The supplied source describes standardized laboratory quantities, protective packaging, and professional shipping arrangements. However, no current inventory information, carrier record, destination-specific authorization, or verified shipment-performance documentation was provided. Consequently, no specific availability, delivery, customs-clearance, or transportation-compliance guarantee is asserted. Gidazepam may be subject to controlled-substance or other chemical regulations. Institutional acquisition and transfer should therefore be assessed against the applicable laws governing the exact substance and chemical form involved. Researchers and institutions should independently verify whether possession, importation, exportation, transportation, and laboratory investigation are authorized in their jurisdictions. Research-only labeling does not establish an exemption from controlled-substance regulations. ## Legal & Regulatory Disclaimer For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications. Gidazepam is a benzodiazepine-related compound whose acquisition, possession, transfer, importation, exportation, storage, and laboratory investigation may be restricted or prohibited under applicable controlled-substance or other chemical regulations. The exact legal classification and requirements may vary by jurisdiction. Researchers and institutions remain responsible for determining the applicable legal requirements and obtaining any necessary authorizations. No medical approval, consumer-use authorization, universal legal status, or regulatory exemption is implied by this description.
Gidazepam pellets – 3mg Price range: € 15,00 through € 175,00

Buy Flubrotizolam Pellets

Price range: € 16,95 through € 299,95

Flubrotizolam Pellets are described as a laboratory research preparation associated with flubrotizolam, a synthetic brominated and fluorinated thienotriazolodiazepine structurally related to brotizolam.

Raw Lab Chems identifies this material exclusively within the context of controlled chemical identification, chromatographic characterization, forensic analytical investigation, and comparative research involving benzodiazepine-related compounds.

The supplied information describes a compressed pellet presentation but does not specify a confirmed labeled ingredient amount for this particular listing.

Claims concerning ingredient purity, independent analytical verification, standardized pellet content, batch consistency, and controlled storage require supporting product-specific documentation.

The material is not established as a certified reference standard or validated quantitative calibrator.

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

SKU: CERT-P-13176 Category:
Description

Flubrotizolam Pellets – Thienotriazolodiazepine Research Material

Product Overview

Flubrotizolam Pellets are described in the supplied information as a laboratory research preparation associated with flubrotizolam, a synthetic compound belonging to the thienotriazolodiazepine family.

The compound is structurally related to brotizolam and is distinguished by its brominated and fluorinated molecular framework.

These structural characteristics provide a basis for analytical investigations involving chemical identification, chromatographic differentiation, and spectroscopic characterization.

Raw Lab Chems presents this material exclusively within a Research Use Only framework.

The supplied source describes compressed pellets intended for controlled laboratory examination.

However, the stated presentation does not independently establish the actual chemical identity, purity, finished-unit composition, or content uniformity.

The source also refers to independent analytical verification, batch consistency, and controlled storage.

These statements originated in material associated with another supplier and cannot be attributed to Raw Lab Chems without independent documentation.

No clinical, therapeutic, diagnostic, dietary, or consumer-oriented application is represented by this description.

Chemical Identity & Classification

Flubrotizolam is described in the supplied source as a thienotriazolodiazepine derivative.

The compound contains a fused thiophene-associated diazepine framework and an additional triazole ring.

Its molecular structure distinguishes it from classical benzodiazepines through the replacement of a benzene ring with a thiophene-containing system.

The supplied source provides the following chemical-reference information:

  • Common name: Flubrotizolam
  • Reported systematic name: 2-Bromo-4-(2-fluorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
  • Chemical classification: Brominated and fluorinated thienotriazolodiazepine derivative
  • Reported CAS Registry Number: 57801-95-3
  • Reported molecular formula: C15H10BrFN4S
  • Reported molecular weight: 377.23 g/mol

These identifiers are reproduced from the supplied information and do not independently verify the composition of the actual product.

The reported molecular formula and molecular weight are approximately consistent with one another.

However, consistency between a formula and calculated mass does not establish that the actual pellet ingredient has been independently identified.

The source does not provide a verified salt-form designation or complete formulation specification.

This distinction matters because the composition of a finished pellet may differ from the molecular formula of the named chemical.

Researchers seeking public chemical-reference information may consult PubChem and confirm that any selected database entry corresponds to the intended compound and chemical form.

Chemical & Physical Characteristics

The supplied product is described as compressed pellets containing flubrotizolam.

No product-specific inspection report, pellet-dimension specification, excipient list, or formulation-characterization record was provided.

The stated physical presentation therefore remains a source-provided description.

The flubrotizolam molecular framework contains a fused thiophene-triazolodiazepine ring system and substituents that distinguish it from related benzodiazepine derivatives.

These structural features provide a basis for analytical differentiation through chromatographic and spectroscopic techniques.

However, structural similarity does not establish identical physical properties, stability, impurity profiles, or analytical behavior.

The source identifies hydroxylated metabolites as topics of forensic and chemical research.

No product-specific hydrolysis-rate measurements, degradation data, or experimentally verified physicochemical profile accompanied this description.

The source also does not provide a verified melting point, quantitative solubility profile, density, particle-size distribution, or hygroscopicity measurement.

The finished pellet preparation may contain additional formulation ingredients that were not identified in the source.

No verified binder, filler, coating, or excipient information accompanied the supplied material.

The source recommends dry, dark storage under controlled temperature conditions and suggests frozen storage for longer-term preservation.

No validated stability study, degradation profile, or experimentally established shelf-life specification accompanied this recommendation.

Purity & Analytical Verification

The supplied description claims purity of at least 98%, with independent quality-control testing cited as verification.

It also refers to analytical purity profiles and Certificates of Analysis.

However, no actual Raw Lab Chems batch-specific Certificate of Analysis, chromatogram, mass spectrum, NMR spectrum, or independent laboratory report was provided.

Accordingly, the stated purity threshold is not independently confirmed for the material described here.

The source identifies LC-MS/MS and LC-HRMS/MS as analytical techniques associated with flubrotizolam investigation.

Such methods may provide information concerning chemical identity, structural characteristics, impurity profiles, and analytical specificity.

However, naming an analytical technique does not establish that it was performed on the actual product.

An important distinction exists between the purity of the chemical ingredient and the composition of the finished pellet.

Even if ingredient purity were independently established, that finding would not by itself verify the labeled component amount, total formulation, or consistency between individual units.

The source also references hydroxylated metabolites as potential analytical markers.

These references provide scientific context rather than evidence of the product’s verified performance in a particular laboratory method.

No certified reference-material status, validated finished-unit content, or independently established purity specification is asserted.

Quality Control & Batch Integrity

The supplied source claims that individual batches undergo independent testing and are supported by Certificates of Analysis.

It also describes standardized pellet content, controlled storage, and double-sealed packaging.

No actual certificate, independent testing record, manufacturing audit, laboratory accreditation document, or batch-specific quality-control report accompanied these statements.

They therefore remain unverified claims. Flubrotizolam Pellets

Furthermore, the source refers to a supplier other than Raw Lab Chems.

Its quality-control representations should not be transferred to a Raw Lab Chems product listing without supporting documentation from the relevant supplier.

For reproducible laboratory investigation, useful records may include supplier identification, batch number, chemical identifier, receipt date, storage history, and available analytical findings.

For pellet preparations, the identity and purity of the named ingredient should be distinguished from the composition and consistency of the finished units.

The supplied information does not establish independently verified content uniformity, excipient composition, or quantitative accuracy of any labeled amount.

Where a material is described as suitable for reference-standard work, researchers should distinguish ordinary catalog material from a certified reference material.

The supplied information does not establish certified reference-material status, metrological traceability, or an assigned measurement uncertainty.

Safety, Handling & Laboratory Precautions

Flubrotizolam is a benzodiazepine-related compound requiring appropriate institutional risk assessment and controlled laboratory handling.  Flubrotizolam Pellets

The source associates the compound with serious central nervous system depressant hazards, including profound impairment and potentially life-threatening toxicity following exposure.

Research personnel should consult applicable chemical-safety documentation and institutional procedures before receiving or examining the material.

Laboratory precautions should address access restrictions, protective equipment, contamination prevention, accidental exposure, environmental release, and chemical-waste disposal.

The compound’s structural relationship to brotizolam does not establish safety for human or veterinary exposure.

The material should remain secured against unauthorized access and separated from food, beverages, and non-research environments.

Because the actual purity and pellet composition have not been independently confirmed, laboratory documentation should distinguish verified characteristics from supplier-provided statements.

The pellet presentation must not be interpreted as evidence of pharmaceutical suitability or authorization for personal use.  Flubrotizolam Pellets

Any accidental exposure or contamination incident should be managed according to institutional emergency procedures.

Packaging, Labeling & Storage

The supplied source describes double-sealed packaging, temperature-controlled logistics, and tracking during transportation.

No Raw Lab Chems packaging-validation study, verified container specification, shipment-condition record, or carrier documentation accompanied these claims.

The source recommends dry, dark storage under controlled temperature conditions and suggests approximately −20°C for longer-term preservation.

It also claims extended stability under frozen storage.

No validated stability data was provided to establish that this temperature is necessary or sufficient for a particular shelf life.

Claims concerning frozen storage, stability duration, and controlled transport therefore remain unverified.

Laboratory inventory records should preserve the compound name, any available batch identifier, receipt details, and relevant storage observations.

Any labeled pellet content should be recorded as a source-provided specification unless independently confirmed.  Flubrotizolam Pellets

Where chemical form or formulation ingredients remain uncertain, the inventory record should preserve those uncertainties rather than assign unverified details.

Packaging and environmental requirements should be assessed using available safety documentation, relevant stability evidence, and institutional laboratory procedures.

Intended Research Use & Market Positioning

The supplied scientific context places flubrotizolam within analytical research involving thienotriazolodiazepine derivatives, chemical identification, structural comparison, and forensic toxicology.    Flubrotizolam Pellets

Its brominated and fluorinated molecular framework provides a basis for differentiating it from other benzodiazepine-related compounds in appropriately validated analytical investigations.

The source references chromatographic identification, mass-spectrometric characterization, and investigation of hydroxylated flubrotizolam-related analytical markers.

These references describe laboratory research contexts and do not establish any human-use application.

For comparative chemical-catalog research, Raw Lab Chems also lists Fluclotizolam Pellets and Fluetizolam Pellets.

These listings identify other named research materials but do not establish equivalent chemical identity, purity, formulation, or analytical characteristics.

The supplied catalog also includes Flunitrazolam Blotters, a different benzodiazepine-related compound presented in another format.

These references provide chemical-catalog context rather than evidence of certified reference-material status or interchangeability.

Ordering, Availability & Fulfillment

The supplied source includes claims concerning available pack sizes, European shipping coverage, same-day dispatch, delivery time frames, carrier services, and payment options.

However, those statements reference another supplier and are not verified Raw Lab Chems fulfillment specifications.

No current Raw Lab Chems inventory record, shipping schedule, destination-specific authorization, or carrier documentation was supplied.

Consequently, no particular availability, delivery period, shipping cost, customs-clearance arrangement, or transportation-compliance guarantee is asserted.  Flubrotizolam Pellets

Flubrotizolam may be subject to strict controlled-substance legislation.

Institutional acquisition and transfer should therefore be assessed against the applicable laws governing the exact substance and chemical form involved.

Researchers and institutions should independently verify whether possession, importation, exportation, transportation, and laboratory investigation are authorized in their jurisdictions.

Research-only labeling does not establish an exemption from controlled-substance regulations.

Legal & Regulatory Disclaimer

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Flubrotizolam is a thienotriazolodiazepine whose acquisition, possession, transfer, importation, exportation, storage, and laboratory investigation may be restricted or prohibited under applicable controlled-substance or other chemical regulations.  Flubrotizolam Pellets

The supplied source identifies regulatory restrictions in the United Kingdom and France, but the exact current legal classification was not independently verified for this listing.

Researchers and institutions remain responsible for determining the applicable legal requirements and obtaining any necessary authorizations.

No medical approval, consumer-use authorization, universal legal status, or regulatory exemption is implied by this description.

Additional information
Quantity

10 pellets

,

20 pellets

,

50 pellets

,

100 pellets

,

250 pellets

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Buy Flubrotizolam Pellets”
Shipping & Delivery